
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics Inc. is well-positioned for future growth due to a notable increase in Chromium reaction volumes, indicating a robust market despite ongoing pricing pressures in the pharmaceutical sector. The company's consumables, which are projected to grow at an impressive rate of 5-19 times by platform by 2027, are outpacing instrument revenue growth, highlighting strong demand for its integrated solutions. Overall, the demand for 10x Genomics's advanced platforms, including the Chromium and Visium systems, reflects the increasing need for high-resolution biological analysis, supporting a favorable long-term outlook for the company's stock performance.
Bears say
10x Genomics has experienced a contraction in 2024, facing double-digit pricing pressure that has negatively impacted revenue, alongside flat to modestly lower volumes, with projected growth not anticipated to recover until 2027. Additionally, the company's recent Q4 results revealed an earnings per share miss, reporting -$0.40 compared to an expectation of -$0.30, coupled with a full-year revenue outlook that fell below market expectations. Since its peak stock prices in 2021, the company has seen a decline of over 90%, indicating that its market segments have not expanded as anticipated, contributing to a negative outlook for the stock.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares